This essay has been submitted by a student. This is not an example of the work written by our professional essay writers.
Cocaine is a highly addictive substance abused worldwide. Its primary mechanism of action involves blockage of dopamine, norepinephrine and serotonin transporters in specific brain regions, mainly the dopamine reuptake system located on mesolimbic neurons. Cocaine increases the dopaminergic neurotransmission and triggers adaptive changes in several neuronal circuits underlying reinforcement, reward, sensitisation and the high addictive potential of cocaine. However, the long-lasting behavioural effects associate with cocaine addiction show there is complex neurotransmitters interaction within the reward circuit. Excitatory amino acid and inhibitory GABA transmitters also play a part in these changes. Glutamatergic systems regulate dopamine function, while GABAergic modulate the release of basal dopamine and glutamate. Understanding of the molecular and cellular mechanisms that lead to cocaine addiction has given new treatment methods in the pharmacological field to develop better medicine. Especially, useful monoamine agonists' treatment may be successfully in controlling behaviour and lead to long term moderation of drug taking. However, more studies are needed in order to identify safe and efficacious pharmacotherapy.
Cocaine, an alkaloid derived from the leaves of Erythroxylon coca is a psychostimulant drug linked to human addiction (Dackis et al., 2001).
Cocaine acts as a local anaesthetic with sympathomimetic and vasoconstrictor properties (White and Lambe, 2003). In addition, cocaine is a potent uptake blocker for dopamine (DA), norepinephrine and serotonin (Carrera et al., 2004). As shown in figure one, the chemical structure of cocaine molecule contains two rings, the six-carbon phenyl ring shown on the right and the unusual nitrogen (N)-containing ring shown on the left, both necessary for its biological activity (Meyer and Quenzer, 2005).
Cocaine acts by blocking the dopamine transporter within the mesocorticolimbic reward system. Blockade of the transporter increases the level of dopamine in this region of the brain. Increased dopamine level is responsible for the euphoric effect of cocaine (Butterner et al., 2003). However, the long lasting effects of behavioural characteristics of cocaine addiction, such as sensitisation and the vulnerability to the reinstatement of drug seeking years after the acute rewarding effects of the drug have disappeared, shows that there must be complex interactions between additional neurotransmitter systems (Kalivas, 2004). In contrast to dopaminergic system, excitatory amino acid and inhibitory GABA transmitters also play a role in these changes. Glutamatergic systems regulate dopamine function, while GABAergic modulate the release of basal dopamine and glutamate (Baler and Volkow, 2006). Additionally, cocaine can also interact with several receptors and ion channels, including nicotinic acetylcholine, and opioid receptors coupled to voltage-gated Ca2+ and K+ channels (Kobayashi et al., 2007), resulting in prolonged elevation of extracellular dopamine.
The potential abuse of cocaine is mainly based on the rapid development of tolerance to the euphoric effects (Butter et al., 2003). Cocaine addiction is an uncontrollable and continually relapsing drug taking disorder (Torregrossa and Kalivas, 2008). The behavioural manifestation of addiction is mediated by adaptations that chronic administration of drug abuse elicits at the level of individual neurons in the CNS. These adaptations alter the functional properties of neurons, which in turn change the properties of the functioning of neural circuits in the brain in which these neurons are involved (Nestler, 1997). The probability that one will become addicted to cocaine depends on the method, the frequency and the duration of one's cocaine intake (Carrea et al., 2004).
1.1. Historical aspect of cocaine use
The use of cocaine for personal satisfaction dated back over thousands of years ago, when Erythroxylon coca, the plant from which cocaine is extracted was used by indigenous people from Andes and South America for religious, mystical, social, and medical purposes (Dackis et al., 2001).
The coca leaf was chewed by these communities because of its euphoric effects and its ability to reduce fatigue and hunger and to enable sustained periods of heavy labour (White and Lambe, 2003).
This leaf was introduced in Europe in 1492 by the Spaniards, when they conquered South America and discovered that this leaf would be useful for performing hard labour (Julien et al., 2008). Eventually, the Spaniards started using the coca leaf as a method of payment for the native worker in gold and silver mine, who would take the leaf to reduce appetite and increase physical stamina.
Cocaine alkaloid was first isolated by a German chemist Friedrich Gaedche in 1855 (Julien, 2008). The ability of cocaine in reducing fatigue and hunger were recognised by Sigmund Freud who used cocaine himself. Freud and others also recognised the ability of cocaine to cure opioid addiction. As a result, Freud prescribed cocaine to his patients who were addicted to morphine (Boghdadi and Henning, 1997). Unfortunately, many of these patients became addicted to cocaine themselves (Grilly, 1998).
Morphine, which is similar to cocaine in reducing hunger, was extracted from opium in the early 1800s by Friedrich Wilhelm Adam Sertürner. But its use spread in 1853 when the hypodermic needle was developed (Grilly, 1998). Morphine was used as a pain reliever and as a cure for opium and alcohol addiction. Its extensive use during the American Civil war resulted with people suffering from the "soldier's disease (addiction)," (Julien et al, 2008).
1.2. Forms of cocaine
The use of crack cocaine, or crack, was first reported in 1980 in Europe and the US as a new drug with rapid stimulating effects. Crack cocaine is a by-product of cocaine, C17H21NO4 (figure 1). However, crack is formed through different processes. First, the coca leaves are transformed into a product known as basic cocaine paste. The paste is then turned into either crack cocaine through chemical treatment with sodium bicarbonate, or into a less potent water soluble salt, cocaine hydrochloride when it is refined with either acetone or sulphuric and hydrochloric acids. The powdered hydrochloride salt can be snorted, and because it is water soluble, it can be injected intravenously (Boghdadi et al., 1997).
However, in the hydrochloride form, cocaine decomposes when it is heated and is destroyed to temperature, making it unsuitable for use by inhalation. In contrast, crack cocaine is converted to a stable vapour by heating it (Julien et al., 2008), making it more potent than the concentrated form. The paste and crack cocaine forms can be smoked either on their own or together with tobacco or cannabis-marijuana and sometime mixed with heroin and sold on the street (Goldstein et al., 2009).
Cocaine hydrochloride compared to crack cocaine, is less potent and it is used as a local anaesthetic. Its use as anaesthetic first came about in 1884, after Niemann described its anaesthetic properties such as bitter taste and the resultant unusual numbness when applied to the tongue (Goldstein et al., 2009). By the late 1800s, when morphine was already used as a pain reliever, the use of cocaine for its analgesic properties which includes nerve blocking anaesthesia, epidural, and spinal anaesthesia has began to spread (Goldstein et al., 2009). Both cocaine hydrochloride and morphine are still used medically today as anaesthetic, despite their addictive properties. Cocaine hydrochloride is used as a vasoconstricting anaesthetic agent in surgery for ears, nose, and throat (White et al., 2003), while morphine is used as anaesthetic to relieve severe pain. Morphine acts through mu, kappa, and delta opioid receptor to block pain messages to the central and peripheral nervous system (Julien et al., 2008), However, morphine produces euphoria by interacting mainly with the mu opioid receptor (rosin et al., 2000).
Aim: The aim of this project is to view the complex interaction between cocaine and cocaine receptors and the mechanisms of action of cocaine. Special emphasis will be placed on cocaine tolerance and addiction. To begin with, an overview will be provided on the pharmacokinetics of cocaine by discussing how it is absorbed, distributed, metabolised and excreted. Then, a discussion on how cocaine-induced changes in the peripheral and central nervous system contribute to the euphoric effect and addiction. Finally, an overview of how cocaine dependency could be treated.
Pharmacokinetics of cocaine
The effect of cocaine on the body depends heavily on the rate of accumulation and the concentration of cocaine at its site of action (the brain) and the duration of contact at these sites (Grilly, 1998). The pharmacokinetics of cocaine refers to its movement in the body with respect to its absorption, distribution, metabolism and excretion from the body and this is dependent on multiple factor such as, route of administration, genetics, and consumption of cocaine (Goldstein et al., 2009).
2.1. Route of Administration/ Absorption
As illustrated in figure two, cocaine is rapidly absorbed from the mucous membranes, the stomach and the lungs. Therefore, cocaine can be snorted, smoked, taken orally, or injected intravenously (Julien et al., 2008). However, the onset and duration of cocaine depends on the method of intake (Grilly, 2006).
Cocaine hydrochloride poorly crosses the mucosal membranes when snorted, due to its vasoconstriction properties, thereby constricting blood vessels and limiting its own absorption. Because of the slow absorption of cocaine, its euphoric effect is prolonged when administered intranasally (Boghdadi et al., 1997).
Cocaine can be also smoked in the form of crack. Because of its rapid absorption in the pulmonary vascular bed, crack produces an intense high in seconds, peaks at 5 minutes and persists for about 30 minutes.
Intravenous injection of cocaine hydrochloride bypasses all the barriers to absorption, placing the total dose of drug immediately into the bloodstream. It produces euphoria in 30-45 seconds (Julien et al., 2008).
After administration, cocaine rapidly penetrates the brain. Initial brain concentrations far exceed the concentration in plasma (Julien et al, 2008). After it penetrates the brain, cocaine is rapidly redistributed to other tissues such as the spleen, kidney, and lungs. Cocaine also binds to plasma protein, albumin and also to Î±1-acid glycoprotein (Boghdadi et al., 1997).
Drugs taken orally initially pass through the liver (Figure 2), where they may be metabolised before entering the blood. Cocaine is metabolised primarily into ecgonine methyl ester and benzoylecgonine (Figure 3), the main urinary metabolite of cocaine and can be detected in urine for about 48 hours and up to 2 weeks in chronic users (Butttner et al., 2003). Cocaine is catalysed to ecgonine methyl ester by serum and liver cholinesterases, while benzoylecgonine is hydrolysed non-enzymaticaly (Carrera et al., 2004). Benzoylecgonine have vasoconstrictive properties, however it does not appear to cross the blood-brain barrier readily (Goldstein et al., 2009.). In addition, cocaine is demethylated to formed norcocaine (Figure 3) (Carrera et al., 2004), the only metabolite of cocaine that crosses the blood-brain barrier (Flowler et al., 2001).
In the presence of ethanol, cocaine is metabolized to cocaethylene (Buttner et al, 2003). Cocaethylene is as active as cocaine in blocking the presynaptic dopamine reuptake transporter, thereby potentiating the euphoric effect of cocaine, increasing the risk of dual dependency and the severity of withdrawal with chronic patterns of use. This metabolite is more toxic than cocaine and aggravates cocaine's toxicity. The half-life of cocaethylene is about 150 minutes, outlasting cocaine in the body (Julien et al., 2008).
Even though cocaine's plasma half-life is about 50 minutes, several metabolites can be detected by way of urinalysis for up to 2 to 5 days after cocaine overdose (Grilly, 2006).
Mechanism of actions of cocaine
Cocaine's euphoric and reinforcing properties are the result of the obstruction of dopamine transporter (Butterner et al., 2003), thus, increasing dopamine level within the mesolimbic dopamine pathways. The mesolimbic dopamine pathways, shown in figure4, are composed of ventral tegmental area (VTA), the prefrontal cortex (PFC), Hipocampus, amygdale, and the nucleus accumbens (NAc) (Cornish and Kalivas, 2001) (figure 5). The nucleus accumbens (NAc) which consists of two sub-regions, the core and the shell, is believed to be the site for both the primary reinforcing properties of drugs of abuse and conditioned control over drug seeking (Kalivas, 2004).
Normally, Dopamine is released into the synapse from an axon terminal in response to a pleasurable signal (Dackis and O'Brien, 2001). Once this neurotransmitter is released, it diffuses across the synaptic cleft to bind to their respective receptors, D1 and D2 receptors (Howell* and Kimmel, 2008), which are linked to the cAMP second messengers system via membrane-bound G-proteins. D1family receptors (D1 and D5) are coupled to a stimulatory G-protein (Gs), which when activated increases the production of adenylate cyclase and cAMP and stimulation of the D2 family receptors (D2, D3, and D4) leads to the inhibition of adenylate cyclase through activation of an inhibitory G-protein (Gi/Go) (Cunningham and Kelley, 1993).
Dopamine is taking back into the presynaptic neurons through the dopamine transporter, as a result shutting off the signal between neurons by preventing new dopamine to be formed (Howell* and Kimmel, 2008).
Cocaine, on the other hand, blocks the dopamine transporter (figure 5), preventing the reuptake of dopamine into the presynaptic neurons of the VTA. Blockade of the transporter augment dopamine level in the synaptic clefts, producing continuous stimulation of dopamine receptors (Anderson and Pierce, 2005). Increasing dopamine concentration in the nucleus accumbens is responsible for the euphoric and reinforcing effects of cocaine.
Repeated cocaine treatment increases dopamine levels in the synaptic cleft, which could lead to further stimulation of the dopamine receptors, causing more intense but shorter behavioural responses (Anderson and Pierce, 2005). This progressive change in behavioural response following repeated cocaine administration is known as behavioural sensitisation or reverse tolerance. The enduring neuronal adaptation in the reward circuit that occur after repeated cocaine administration is believed to be associated with motive and reward (Morgan and Roberts, 2004). The neuroadaptations that result in behavioural sensitization is characterised by two processes, known as initiation and expression (Anderson and Pierce, 2005). Initiation, which takes place in the VTA, is referred to as temporary cellular and molecular changes, such as alteration in various genes, second messenger cascades and receptors densities, which occur in response to psychostimulant administration, while expression is the long-lasting neuronal changes that start from the VTA and progress to the nucleus accumbens and striatum to increase behavioural response (Pierce and Kalivas, 1997).
It has been reported that repeated cocaine treatment for two weeks increases the sensitivity of dopamine D1 receptors in the olfactory tubercle, nucleus accumbens, ventral pallidum, and substantia nigra and subsensitivity of D2 receptor (Unterwald et al., 1996). Activation of D1 receptors stimulates adenylyl cyclase activity via activation of Gs; increasing sensitivity of D1 and also increased adenylate cyclase and cyclic AMP-dependent protein Kinase (PKA) activity in the nucleus accumbens due to continual activation of Gs protein (Cunningham and Kelley, 1993). However, continuous cocaine treatment decreased D1-like receptor density and function, thereby initiated behavioural tolerance (Keys, and Ellison, 1994).
Increased release of dopamine in the nucleus accumbens is also calcium-dependent and relies upon activation of calcium-dependent proteins, calmodulin and calcium-calmodulin kinase II (CaM-KII (Pierce and Kalivas, 1997). It is generally believed that increased calcium conductant and activation of calcium-dependent protein kinase are involved in the release of neurotransmitters in presynaptic nerve terminals and initiation of gene transcription (Evans and Zamponi, 2006). Therefore, continuous activation of calmodulin and CaM-KII by cocaine in the nucleus accumbens may mediate the release of dopamine or other neurotransmitters such as glutamate and GABA that are associated with expression of behavioural sensitisation (Pierce and Kalivas, 1997).
D1 receptors located on GABA and glutamate afferents to the VTA are responsible for the release of these neurotransmitters in the nucleus accumbens when activated. Interaction between these neurotransmitters in the VTA changes the regulation of dopamine cell, which initiate long-term neuroadaptations (Cornish and Kalivas, 2001).
4.1. Glutamatergic systems
Excitatory amino acid such as glutamate acts as the main mediators of excitatory signals in the central nervous system (Baler and Volkow, 2006). Glutamate is known to produce its action through ionotropic (NMDA and non-NMDA) and metabotropic (mGluR) subclasses receptors (Danbolt, 1997). Although cocaine does not have a direct influence on brain glutamate systems, repeated exposure to cocaine results in alterations in glutaminergic transmission in the nucleus accumbens (Schmidt et al., 2005). However, the PFC, which transmits major glutaminergic projections to the nucleus accumbens (figure 4) has been most implicated in the regulation of dopamine released from dopamine cell terminals through NMDA and non-NMDA receptors (Kalivas, 1997). It is believed that stimulation of NMDA receptors through a voltage-dependent calcium channel initiate burst firing model in dopamine cells, as a result increasing accumbal dopamine release which is similar to what occurs in behavioural sensitisation (Evans and Zamponi, 2006).
Administration of cocaine increases dopamine release presynaptically, which stimulates dopamine D1 receptors, located on descending glutamatergic afferent terminals from the prefrontal cortex (PFC). The D1 receptor in turn, stimulates the release of glutamate in the prefrontal cortex postsynaptic neuron. The released glutamate activates NMDA receptors on the dopaminergic dendrites in this brain area. This sequence of events is augmented by the fact that repeated cocaine administration desensitises dopamine D2 autoreceptors. Desensitisation of D2 receptor reduces the hyper-polarisation of dopamine cells, thereby allowing a further augmentation of dopamine release, which causes supersensitivity of D1 receptors, hence, increasing NMDA activity (Johnson and North, 1992).
Because the neuronal circuits are interconnected (figure 5), a reduction in PFC dopamine transmission will activate the nucleus accumbens dopamine release, leading to expression of behavioural sensitisation. Increased glutamate release from the PFC to nucleus accumbens' core is associated with cocaine-induced reinstatement and expression of locomotor sensitisation (Torregrossa and Kalivas, 2008).
Both Glutamatergic and GABAergic neurons are also joined in the prefrontal cortex, indicating a possible interaction between glutamate and GABA. Therefore, the PFC GABA transmission may also be involved in the development of behavioural sensitisation (Giorgi et al., 2005).
4.2. GABA systems
It has been reported that cocaine sensitisation is linked with a cocaine-induced increased glutamate and GABA levels in the PFC. This was supported by Jayaram and Steketee (2005), who observed an increase in both glutamate and GABA concentration in the prefrontal cortex of animals withdrawn from repeated daily cocaine after the first week following repeated exposure to cocaine, but increase in these neurotransmitters were not observed after prolonged withdrawal. Furthermore, Jayaram and Steketee reported that the AMPA/KA receptor antagonist, (DNQX) prevent cocaine from increase the concentration of GABA in the prefrontal cortex in cocaine-sensitised animals. Therefore, increasing the response of GABAergic neurons in the PFC is a consequence of enhance glutamate level in prefrontal cortex. Because the AMPA/KA receptor antagonists seem to block cocaine from augmenting GABA levels, it can be concluded that glutamate acts mainly through AMPA/KA receptors to increase GABAergic activity in the prefrontal cortex.
However, decrease in GABAÎ² receptors function in the PFC is also associated with sensitisation of locomotors. It is believed that a loss in GABAÎ² function in the prefrontal cortex would lead to a decrease in inhibitory modulation of excitatory pyramidal output neurons in the PFC (Badran et al., 1997), and therefore, a simultaneous increase in glutamatergic transmission in subcortical regions associated with the expression of behavioural sensitisation (McFarland et al., 2003).
Glutamatergic, GABAergic and midbrain dopamine neurons are joined onto dendritic spines of medium spiny neurons that contain GABA, and endogenous opioid peptides. These opioid-containing neurons project directly to the substantia nigra and VTA to synapse on dopamine cells (Yung and Bolam, 2000). Therefore, alteration of endogenous opioid may participate in the development of drug abuse.
4.3. Opioid systems
It has been suggested that dopamine and opioid act together to modulate locomotion, mood and motivated behavioural, therefore, modification of the endogenous opioids participate in the development of drug of abuse. In addition the opioid system could also influence drug craving and relapse by altering stress physiology (Rosin et al. 2000). Apart from dopaminergic system, the endogenous opioid system is also a major player in addiction. Opioid system consists of three G-protein coupled receptors, termed mu (Î¼), kappa (Îº), and delta (Î´) opioid receptors. They act through G-protein second messenger systems (Go/Gi) to inhibit adenylate cyclase and cyclic AMP (Contet et al., 2004). Activation of these receptors on presynaptic axon terminals inhibits the Ca2+ influx that underlies release of neurotransmitters (Evans and Zamponi, 2006). At the postsynaptic membrane, their activation hyperpolarises the membranes by enhancing K+ flow out of neurons (Taddese et al., 1995)
4.3.1. mu (µ)-opioid receptor
Mu (µ) opioid receptors mediate positive reinforcement following direct morphine or indirect alcohol, cannabinoids and nicotine activation (Jullien et al, 2008). The positive reinforcing and euphoric effect of morphine involved dopaminergic as well as mu opioid receptors. Morphine activates Î¼-opioid receptors through inhibitory Go/Gi protein, which decreases the level of adenylate cyclase and the cAMP pathways in the VTA (Contet et al, 2004). Because opioid and GABA containing-neurons also project in the VTA, activation of µ receptor inhibits the release of GABA on dopamine, leading to high level of dopamine in the nucleus accumbens and other area. The increase in dopamine level in the nucleus accumbens leads to the positive reinforcement of opioid addiction (Bartoletti et al., 1999), which is also related to cocaine reinforcing effect (Julien et al., 2008). Stimulation of µ opioid receptor in the VP is thought to promote motor activity, in part, by reducing presynaptic release of GABA (Torregrossa and Kalivas, 2008). Repeated cocaine administration results in reduced extracellular GABA in the VP due to increasing stimulation of presynaptic µ opioid receptors (Tang, et al. 2005).
4.3. 2. K-opioid receptors
Îš-opioid receptor system is essential in regulating presynaptic dopamine release and administration of dynorphin (DYN) within the nucleus accumbens (Shippenberg and Rea, 1997). DYN, endogenous ligand for the Îº-opioid receptor prevents the sensitisation that develops to locomotor stimulatory and conditioned reinforcing effect of cocaine. Anatomical studies have shown interaction between the mesolimbic dopamine neurons and neurons containing the opioid peptide dynorphin (Yung and Bolam, 2000. As mentioned above, dynorphin are found in dentritic spine of medium spiny neurons and project to the VTA and nucleus accumbens in which Îº-opioid receptors are expressed. However, the accumbens shell express high density of Îº-opioid receptors (Jayaram and Steketee,).
Microdialysis studies have shown that the systemic administration of selective Îº-opioid receptor agonists such as U50488 and U69593 depress the firing rate of mesolimbic dopamine neurons and decreases dopamine overflow in the nucleus accumbens (Shippenberg and Rea, 1997). Therefore, activation of Îº-opioid receptor will inhibit dopamine release in the nucleus accumbens. However, Kuzmin et al., 1997 showed that acute administration of selective Îº-opioid receptor antagonist, nor-binaltorphimine increases dopamine overflow within the nucleus accumbens. In addition to these findings, it is believed that dopamine D1 or D2 receptor agonist, apomorphine, increases dynophin immunoreactivity and prodynorphin mRNA in the nucleus (Li et al., 1990). Therefore, repeated administration of cocaine increases prodynorphin mRNA in the nucleus accumbens and striatum.
Taken in to account all these findings, and the role of Îº-opioid receptors in presynaptic modulation of dopamine release, it can be concluded that an increase in the extracellular level of dopamine within the nucleus accumbens results in a compensatory increase in the activity of dynorphinergic neurons. However, this increase is insufficient to prevent the development of behavioural sensitisation.
Because many of the above intracellular adaptation involve changes in protein levels, it can be though that regulation of gene expression may be involved in the long-lasting effects of cocaine.
4.4. Cocaine regulates gene expression
It has been reported that one of the early molecular events following cocaine administration is the activation of nuclear protein (CREB) (Konradi et al., 1994). CREB control the changing that occur in synaptic neurons through modulation of the expression of several cAMP-inducible genes. CREB is regulated via phosphorylation at serine-133 (Konradi et al., 1994) The kinase inducible domain (KID) that contains serine-133 amino acid residue is phosphorylated by cAMP-dependent protein kinase A (PKA), and Ca2+/calmodulin-dependent protein kinases II and IV (CaMK II and IV) (Lonze and Ginty, 2002). Phosphorylation of CREB by PKA and CaMK II and IV results in the expression of immediate early genes (IEGs) including Fos and Jun, which are members of the transcription factor activator protein-1 (AP-1) family (Soderling, 1999).
Acute cocaine administration activates DNA-binding activity of the AP-1 and expression c-Fos, FosB and JunB proteins (Hope et al., 1992). Chronic cocaine exposure is believed to reduce the capability of cocaine to express c-Fos, JunB and FosB proteins. This results in prolonged accumulation of âˆ†FosB proteins (a shorter splice-variant of FosB), which produces more persistent AP-1 complex (Hiroi et al., 1997). Prolonged accumulation of âˆ†FosB was reported in a variety of knockout and transgenic mice studies.
Hiroi et al (1997) showed that mice lacking Fos-B and its shorter splice- variant âˆ†Fos-B had reduced AP-1 complexes following chronic cocaine exposure and increases cocaine-mediated hyper-locomotion and conditioned place (CPP) preference. They also observed that the long-term over expression of âˆ†Fos-B increases AP-1 complexes and behavioural sensitisation in both the nucleus accumbens and striatum. Increased neuronal expression of Fos in these regions after cocaine treatment is mediated by increasing D1 dopamine receptor activation, due to high level of extracellular dopamine.
Chronic cocaine administration repeatedly stimulates dopamine receptors, as a result, decreases the concentration of dopamine within mesolimbic system and the remaining receptors become less sensitive to dopamine. Decrease in dopamine concentration leads to tolerance.
This has been reported in several studies. For example, Maisonneuve et al (1995) observed a reduction in the basal dopamine concentration of rat's nucleus accumbens when 10 or 15 mg/kg of cocaine was administered three times every day per hour for 13 days. Additionally, Inada et al (1992) showed that repeated cocaine administration in rats, reduced dopamine response to cocaine striatum 24 h after withdrawal. Decrease in dopaminergic level also leads to behavioural tolerance.
Tolerance refers to a decrease in response to cocaine due to repeated exposure of the drug (Maisonneuve et al., 1995). The major contributory factor to tolerance is the supersensitivity of D2-like autoreceptors as a result of D1 receptors desensitisation after chronic cocaine treatment (King et al., 1994). King et al showed that following chronic administration of 40 mg/kg of cocaine per day, for 7 days, increases sensitivity of D2-1ike receptors in the nucleus accumbens. Increasing D2 receptors leads to a transient decrease in the levels of GiÎ± and GoÎ± proteins linked to these receptors (King et al., 1994).
Continuous cocaine administration produces tolerance to the inhibitory effects of cocaine on dopamine uptake in striatum and nucleus accumbens. Therefore, blockade of dopamine uptake by cocaine produces a compensatory increase of dopamine reuptake transporters (Letchworth et al, 2001). However, repeated cocaine treatment decreases the mRNA expression of dopamine transporter in the VTA neurons that project to the limbic brain regions during withdraw (Hammer et al., 1997).
Polymorphism in the genes of dopamine transporter (DAT1) and receptors could be implicated in the genetic susceptibility to the complications of long-term development use in different individual (Wang et al., 2004).
There are two main types of DAT1 genes, the SLC6A3 gene and the 3' untranslated VNTR polymorphism. The SLC6A3 is localised to chromosome 5p15.3 and genetic variation in SLC6A3 are thought to change the expression of DAT1 (Fuke et al., 2001). The variable number tandem repeat (VNTR) polymorphism in the 3'untranslated region of DAT1 consists of a 40-bp repetitive sequence and can vary from 3 to 12 repeats. However the two most common alleles are the 9-repeat and the 10-repeat, and several studies have linked these polymorphisms to prolonged psychosis following stimulant withdrawal. Fuke et al (2001) reported that the 10-repeat allele (10R) enhances the expression of the DAT1 protein, while Michelhaugh et al (2001) claimed that the 9-repeat allele (9R) enhanced the DAT1 expression. However both studies found that the DAT1 VNTR is associated with drug addictions.
The gene for D2 dopamine receptor (DRD2), TaqI A (rs1800497) is a single-nucleotide polymorphism (SNP) with two variant; A1, the less frequent allele, and A2, the commoner allele. Accumulative evidence from post-mortem brain samples using a [3H] binding ligand and in living subjects using positron emission tomography (PET) showed that the presence of the A1 allele leads to a decrease in D2 dopamine receptor density, as a consequence of chronic cocaine treatment (Thompson et al. 1997). Therefore, the DRD2 A1 allele is implicated in addictive behaviours. Several studies on different populations suggested that the involvement of TaqI A and VNTR in psychiatric disorders and drug addictions may provide information why some people succumb to cocaine addiction very easily. For example, people from North China, specifically, Han ethnic population and Caucasian have high level of DRD2 TaqI and DAT1-9R and it is believed that those are more likely to develop cocaine dependence (XU et al 2004). In contrast, the DRD2 TaqI A and the DAT1 3'VNTR did not give rise to protein variants that increase susceptibility to cocaine dependency among individuals of African descent (Lohoff et al. 2010).
Chronic cocaine treatment can also reduce immediate early gene responses. For example, Persico et al (1993) show that mRNA of c-fos and zif/268 in the caudatoputame (CP) and nucleus accumbens shell decreased when rats were injected with 15 mg/kg of cocaine twice every day for 10 days, while cortical neurons remained the same (hammer et al., 1997). Additionally, zif/268 mRNA expression decreases in the striatum following repeated injection of three hourly cocaine treatments every day for 10 days. There is also an instant decrease of behavioural responses to cocaine following the reduction of zif/268 mRNA expression, suggesting that reduction of zif/268 mRNA can reflect the presence of behavioural tolerance (Hammer et al., 1997). Zif/268 is one of the several genes encoding the zinc finger protein Krox-24 (Daunais et al., 1995).
Dynorphin also participated in the intracellular events that are associated to the development of tolerance.
Stimulation of Îº-opioid receptors decreases the behavioural effect of cocaine, by reducing dopamine concentration in the nucleus accumbens (Hammer et al., 1997). Repeated administration of cocaine can also increase prodynorphin mRNA expression in rats, suggesting that initiation of behavioural tolerance help the increase prodynorphin (Daunais et al., 1993).
Cocaine increases phosphorylation of CREB protein, which binds to cAMP response elements contained within the promoter region of the prodynorphin gene, to directly induce prodynorphin mRNA expression in dorsal and ventral striatum neurons (Hammer et al., 199). Therefore, phosphorylation of CREB increases dynorphin concentration, which promotes attenuation of immediate early gene expression, thereby, decreasing the reinforcing and behavioural potency of cocaine treatment (Hammer et al, 1997). As a result, alteration in gene regulation in striatal pathways may lead to development of cocaine tolerance
Dependency/Addiction to cocaine
Cocaine dependence is characterised by compulsive cocaine seeking and continued cocaine use despite adverse consequences (Torregrossa and Kalivas, 2008). Cocaine addiction is similar to molecular and cellular mechanism of learning and memory processes, which take place in the hippocampus, hence, cocaine addiction also requires the participation of hippocampus formation (Everitt and Robbins, 2005). Although the hippocampus is not considered an important component of the addiction pathway, it is connected to mesocorticolimbic dopamine system and glutamatergic corticolimbic circuitry. It has been shown that glutamatergic afferents in the hippocampus are responsible for the depolarisation of nucleus accumbens neurons through activation of AMPA-type glutamate receptors (GLuR1). The hippocampus can as well activate dopaminergic neurons of the VTA as the neuronal circuits of the reward system are interconnected (Thompson et al., 2002). Stimulation of the hippocampus inactivates the ventra subiculum, the major source of hippocampal innervations to the nucleus accumbens. Inactivation of ventral subculum reinstates drug-seeking behaviour, (Sun and Rebec, 2003).
7.1. Involvement of corticotrophin-releasing factor (CRF) in cocaine addiction
Corticotrophin-releasing factor (CRF)-related peptides are the main regulator of the stress response (Przegalinski et al, 2005). Stress is a well-known risk factor that increases the development of addiction and vulnerability to relapse (Guan et al., 2009). On the other hand, cocaine withdrawal can result in stress (2007). CRF-related peptides interact with two different G-protein-coupled receptors, corticotrophin- releasing factor receptor subtype 1 (CRF1) and corticotrophin-releasing factor receptor subtype 2 (CRF2) (Wu et al., 2008). Przegalinski et al (2005) reported that blockade of CRF1 reduced stress-induced reinstatement of drug-seeking behaviour in rat. The implication of CRF related peptides and their receptors in cocaine-induced changes of synaptic plasticity were reported by Fu et al (2007). They reported that CFR in vivo can enhance long term potentiation in amygdale after cocaine withdrawal. Additionally, chronic cocaine exposures after synaptic plasticity in lateral septum change the activity of CFR2 (Liu et al., 2005). Therefore, CFR produced a long lasting enhancement of synaptic efficacy in the hippocampus.
7.2. Brain-derived neurotrophic factor (BDNF) in cocaine addiction
Brain-derived neurotrophic factor (BDNF) and its intracellular signalling pathways are believed to be involved in neuroadaptive changes in the dopaminergic or glutamate systems (Thomas et al., 2008). BDNF is expressed in glutamatergic pyramidal neurons arising from the prefrontal cortex as well as dopaminergic neurons arising from the VTA, both of which synapse on GABAaergic medium spiny neurons within the nucleus accumbens. BDNF itself is transported to the striatum where it binds to tropomyosin receptor kinase B (TrkB) receptors on medium spiny neurons (Bibel and Barde, 2000). BDNF activation triggers changes in TrkB mediated intracellular signalling and transcription factor activity (Lu, 2003). Several studies on rodents showed that acute and chronic administration of BDNF can have effect on behavioural paradigms, including cocaine self-administration, cocaine seeking and conditioned responses to cocaine (Lu et al., 2004). Taken together, these studies suggest that neurotrophic factors play an important role in the pathophysiology of cocaine addiction or addictive behaviour.
7.3. Dopamine receptors in cocaine addiction
Dopamine receptors activation are the key players in cocaine addiction since D1 dopamine receptors activation is required for the start of the long lasting potentiating (LTP), through the signalling cAMP synthesis, which activate PKA and stimulate transcription factor CREB (Huang and Kandel, 1995). Chronic cocaine self-administration increases PKA activity in the hippocampus, facilitating the activation of CREB transcription which is implicated in the development of drug addiction (Lu et al., 2003). This process is mediated by activation of dopamine D1 receptors linked to adenylyl cyclase activity, which increases cAMP levels and PKA (Carlezon et al., 1998).
Carlezon et al (1998) have demonstrated the role of CREB in the nucleus accumbens of rats, which acts to reduce dopamine signalling, in morphine and cocaine addiction. They noted that over expression of in the accumbal's shell reduced the rewarding effect of cocaine and morphine. However, over-expression of non-mutated CREB, such as mutation on the serine-133 through a viral vector in the shell of the nucleus increases the rewarding properties of cocaine and morphine (Carlezon et al., 1998).
Other experimental studies also found that injection of phosphodiesterase inhibitor, rolipram, into the nucleus acumbens of rats increases cAMP concentration in this area, as a consequence, blocking the initiation of cocaine self-administration and alter the brain stimulation reward for cocaine (knapp et al., 1999). In addition, Walters et al (2003) reported that mice who have part of their CREB gene removed showed an increased preference for cocaine. Taking into account of these studies, it can be concluded that decreasing CREB function in the nucleus accumbens may promote cocaine administration to achieve an increase in reward, which is involved in the regulation of positive affective states of addiction.
Cocaine as a local anaesthetic: Involvement of Voltage gate sodium channels
Local anesthetics are known to bind Na+ channels in the closed, open, and inactivated states and reach their binding sites via extracellular and intracellular access pathways (Rang et al., 2007). Voltage-gated Na+ channels are involved in generating the action potentials in excitable cells. The major structural component of the channel such as ion selectivity, gating, and ligand binding are located in Î± subunit of Na+ channels (Bruhova et al., 2008). The Î±-subunit is composed of four repeated domains, domain I-IV, each consisting six trans-membrane segments (S1-S6), separated by intra and extracellular loops (Erringtona et al., 2005). Cocaine enters through the open intracellular gate of the channel and move along the ion-conducting hydrophilic pathway to its binding site in the inner pore. Cocaine reaches the inner pore of the closed channel via a hydrophobic pathway (Rang et al., 2007). Blockage of the Na+ channels by cocaine prevents voltage-dependent Na+ conductance, which results in local nerve block (figure 8.a) (Bruhova et al., 2008). Smoking, snorting, or intravenous injection of cocaine can produce acute pulmonary complications. The pulmonary complications are due to cocaine's local anesthetic and sympathomimetic effects, and most commonly are due to smoking crack cocaine ( Boghdadi et al 1997).
Cardiovascular effects of cocaine
Generally, cardiac complications are common cause of death amongst cocaine users and can happens after acute or chronic abuse (Skoutakis, 1982). Myocardial ischaemia and infraction usually occur in cocaine addicts; however, infraction can occur after initial use. Cocaine has usually a positive ino-chronotropic action on the heart, through peritheral and central stimulation of the sympathetic nervous system, by blocking the norepinephrine transporter, as a result increasing the peripheral norepineprine concentration in the synapse, which results in long-lasting activation of the sympathetic nervous system (White and Lambe, 2003). Gillis et al (1995) reported that acute or chronic administration of cocaine increases heart rate, mean arterial blood pressure, cardiac output, left ventricular end diastolic pressure and coronary vascular resistance. It was also reported that the myocardial oxygen demand is increased, while the myocardial oxygen delivery is reduced, as a consequence of increased left ventricular end diastolic pressure, myocardial arteriolar vasoconstriction, and reduced coronary diastolic filling time during tachycardia (White and Lambe, 2003). Myocardial ischaemia is the result of the imbalance between oxygen supply and demand and also the supply of blood is shunted away from the heart to the spleen/liver.
Current treatment strategies of cocaine dependence/addiction
The development of pharmacotherapy for cocaine addiction is focusing on the neurobiological and the behavioural bases of addiction (Carrera et al, 2004). Based on the theory that chronic cocaine use reduces the efficiency of central dopamine neurotransmission and cocaine dependence is strongly associated with depression, dopamine agonists and antidepressants have been used as the main medication in cocaine addiction.
For example, bromocriptine, a D2-like receptor agonist and a partial D1-like receptor agonist used mainly in the treatment of Parkinson's disease, has been reported to significantly reduce cocaine craving and blocked the euphoric effects of cocaine, however clinical trials have fail to support this theory. The indirect dopamine agonist, Disulfiram, which is mainly used in the treatment of alcoholism (Sofuoglu, 2005) has been shown to be effective in clinical trials for the treatment of cocaine abuse. Disulfiram acts by blocking the conversion of dopamine to norepinephrine by inhibiting the enzyme dopamine Î²-hydroxylase, thereby increasing brain dopamine concentrations (Carroll et al., 2004).
Desipramine was the first medication reported to be effective in an outpatient controlled clinical trial. Desipramine was found to be effective in reducing relapse to cocaine use but subsequent clinical trials did not confirm its effectiveness or found it effective only for limited periods (Howell, 2007). Other antidepressants such as fluoxetin and bupropin are not that effective (Hollister et al., 1992).
The ineffectiveness of these medicines may be due to the complex molecular and cellular events in the rewarding circuit that leads to addiction.
Because L-type calcium channel blockers potentially reduce the rewarding effects of cocaine, Carrera et al (2004) reported that isradipine, an L-type calcium channel blocker, attenuated cocaine induced dopamine release in the striatum of rats. And also, pretreatment with isradipine resulted in a dose-dependent decrease in intravenous cocaine self-administration. Combination of isradipine and naltrexone, an opioid antagonist use in the treatment of heroin and alcohol addiction can partially reduced the reinforcing properties of cocaine (CRAMER et al., 1998).
Therefore, another strategy in treating cocaine addiction may be combination of different pathway antagonist.
New approaches to the treatment of cocaine addiction
Since many of the adaptations that lead to addiction occur in cortical circuits that involve glutamate and GABA neurotransmission, current pharmacotherapeutic approaches are focusing on how to modulate glutamate and GABA plasticity (Baler and Volokow, 2006). Topiramate, a glutamatergic agent and Gamma-Vinyl-GABA (GVG), Vigabatrin, an antiepileptic drug have shown some promise for the treatment of cocaine addictions. Vigabatrin works by increasing GABA activity and attenuating drug-induced increases in extracellular nucleus accumbens dopamine as well as the behaviours associated with this dopamine increase (Baler and Volkow, 2006).
In another approach in the development of new treatments for cocaine dependence is the development of new dopamine reuptake inhibitors, which may substitute for cocaine and reduce craving and relapse (Caroll et al., 2006).
Additionally, a cocaine vaccine, termed TA-CD, is in clinical trial. TA-CD is created by attaching succinyl norcocaine (SNC) molecules to a large protein molecule, which is then used to stimulate the body's immune system to produce antibodies that recognise and bind any cocaine taken. It is believed, if the vaccine can bind to cocaine molecule and prevent it from reaching the brain to release dopamine from the synaptic cleft, then the reinforcing effect of cocaine will be reduced (Martell et al., 2005).
Another approach in treating addiction is methadone maintenance treatment (MMT) (Garrido and Troconiz. 1999). Methadone is an opioid agonist with morphine like properties, used as maintenance drug for opioid Methadone binds to mu opioid receptors to produce its effects. The MMT programs, which are designed for rehabilitation and reduction of illicit drug use, have been affective in heroin addicts. Patients that undergo MMT were able to control heroin intakes and also alcohol use (Rosenblum et al., 1999). However, MMT in cocaine dependence have been ineffective (Dobler-Mikola et al., 2005). This may be due to complex neurotransmitters interaction in the rewarding system. Therefore, activation of opioid pathway by methadone may lead to alteration of another pathway, which may promote cocaine dependence.
Cocaine abuse is recognised worldwide and represents a major concern for public health. At present, there is no pharmacological treatment for cocaine addiction that can be effective for long-term use. The understandings of the molecular and cellular effects of cocaine have given new lead in the development and improvement of functional medications for cocaine abuse and dependence. Accumulative evidences have supported the importance of monoamine in the behaviour and long-lasting effects linked to cocaine addiction. Especially dopamine, which is important for neuroplastistic of the reward centre that lead to addiction. However, glutamatergic systems that regulate the dopamine function and GABAergic system that modulate dopaminergic and glutamatergic function promote the molecular and cellular mechanism that lead to behavioural effects of cocaine. Repeated exposure to cocaine leads to prolonged changes in these neurotransmitters, resulting in behavioural sensitivity, as well as dysregulation of the reward circuit linked to dependence and cocaine addiction. Current medications use in the treatment of cocaine abuse and dependence has not been that successful, however, functional agonist treatment or combination of agonists' treatment may be effective in stabilising neurochemistry, influence behaviour and lead to long term abstinence. The fact that glutamatergic and GABAergic agonists agent show to be effective in reducing cocaine use and prolonged cocaine abstinence, and also the development of cocaine, show that current treatment of addiction are improving. However, additional clinical studies are required in order to identify safe and effective pharmacotherapy. Identification of genetic polymorphism in individual may provide important new information in the pathophysiology and eventually may lead to effective therapies.